Last reviewed · How we verify

NCT04375982: NOVEL-3

Evaluation of the LumiraDx Point of Care D-Dimer and CRP Tests

Status unknown NA Last updated 26 December 2023
What this trial tests

NA trial testing Venepuncture in Embolism and Thrombosis in 200 participants. Status unknown.

Timeline
20 April 2020
Primary endpoint
5 April 2022
31 March 2024

Quick facts

Lead sponsorLumiraDx UK Limited
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment200
Start date20 April 2020
Primary completion5 April 2022
Estimated completion31 March 2024
Sites4 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

LumiraDx UK Limited — full company profile →

Who can join

18 and older, any sex, with Embolism and Thrombosis or Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Multicenter Study Conducted to Evaluate the Agreement between Fingerstick Whole Blood, Venous Whole Blood and Plasma Determined on the LumiraDx Point of Care D-Dimer and Point of Care CRP Tests to Results on the Reference Analyzer

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Performance Evaluation of the Quantitative Point-of-Care LumiraDx D-Dimer Test.
    Ellis JE, Johnston TW, Craig D, Scribner A, et al · · 2021 · cited 5× · PMID 34618321 · DOI 10.1007/s40119-021-00241-7

Verify or expand the search:

Other trials of Venepuncture

Trials testing the same drug.

Other recruiting trials for Embolism and Thrombosis

Currently open trials in the same condition.

Other LumiraDx UK Limited trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04375982.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing